F-star Therapeutics, Inc.
FSTX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for FSTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Sep 30, 2022.
Tracking 4 pipeline candidates for F-star Therapeutics, Inc..
Run F-star Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available F-star Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
7.2 months
D/E 0.47
Lead: Phase 2
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Frequently asked questions
What is F-star Therapeutics, Inc.'s lead drug candidate?
F-star Therapeutics, Inc.'s most advanced tracked candidate is fs118 (Phase 2) for PD-1/PD-L1 acquired resistance head and neck cancer, CPI-naïve non-small cell lung cancer (NSCLC), and diffuse large B-cell lymphoma (DLBCL).
Who is the CEO of F-star Therapeutics, Inc.?
Eliot Forster is the chief executive officer of F-star Therapeutics, Inc. (FSTX).
What therapeutic areas does F-star Therapeutics, Inc. focus on?
F-star Therapeutics, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.